Regina Alemany

Research Institute of Health Sciences — Spain

Medicine · Health Sciences

27h-index2.0kcitations89works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(17), Cancer-related gene regulation(13), Sphingolipid Metabolism and Signaling(9), Neurotransmitter Receptor Influence on Behavior(8), Lymphoma Diagnosis and Treatment(8)

Publications89 total

Deciphering WNT Signalling Vulnerabilities in Soft Tissue Sarcoma
Pathobiology·2025
Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience
Frontiers in Immunology·2023Open Access
937P Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment
Annals of Oncology·2023· 1 citedOpen Access
Supplementary Figure 2 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Supplementary Figure 3 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Supplementary Figure 3 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Data from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Supplementary Figure 1 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Supplementary Information from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Supplementary Figure 1 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Supplementary Information from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Supplementary Figure 2 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
Data from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
2023Open Access
SUPPLEMENTARY MATERIALS AND METHODS from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
2023Open Access
SUPPLEMENTARY MATERIALS AND METHODS from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
2023Open Access
Supplementary Figure 2S - Lineweaver-Burk diagram for the substrate RH123 (A) and CFDA (B) in the absence (vehicle, DMSO) or presence of nilotinib (1-10 μM). from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
2023Open Access
Data from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
2023Open Access
Supplementary Figure 3S - Relative mRNA expression of ABCB1 (P-gp) and ABCC1 (MRP-1) in pre- and post-treatment formalin-fixed paraffin-embedded (FFPE) tumor samples. from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
2023Open Access
Supplementary Figure 3S - Relative mRNA expression of ABCB1 (P-gp) and ABCC1 (MRP-1) in pre- and post-treatment formalin-fixed paraffin-embedded (FFPE) tumor samples. from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
2023Open Access
Supplementary Figure 2S - Lineweaver-Burk diagram for the substrate RH123 (A) and CFDA (B) in the absence (vehicle, DMSO) or presence of nilotinib (1-10 μM). from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Oliver Vögler(20), Pablo V. Escribá(13), Javier Martín‐Broto(13), Francisca Barceló(11), Antonio Gutiérrez(9), Gabriel Olmos(9), Valentina Ruíz-Gutiérrez(8), Rafael Ramos(8), Antònia Obrador‐Hevia(8), Dagmar Meyer zu Heringdorf(7), Karl H. Jakobs(7), Jordi Martínez-Serra(7), Jesús A. García‐Sevilla(7), Víctor H. Villar(5), Silvia Calabuig‐Fariñas(5), Esther Martinez-Font(5), Teresa Ros(5), Chris J. van Koppen(4), Holger Lass(4), Javier S. Perona(4)